Neuroinflammation Pipeline Enables Patient Selection and PD
THE NEED
- Chronic neuroinflammation correlates with poor outcomes in a wide range of diseases (e.g. ALS, Alzheimer’s, Parkinson’s)
- Neuroinflammation is difficult to diagnose, and current agents lack sufficient selectivity
OUR SOLUTION
- Radiolabeled (18F) HD, selectively images neuroinflammation in multiple animal models
- Enables patient selection followed by treatment with anti-neuroinflammatory agent coupled to HDT to target reactive microglia
- Observed to cross BBB in 7 species (young and aged)
STATUS:
Risk share via partnership for OP-801 while still maintaining companion diagnostic rights in neurology and cancer applications
Leveraging OP-801 to Achieve Human POC
OP-801: Powerful Proof of Concept for Selective Targeting
Imaged 60 minutes after OP-801 dose
